All In Biotech

Drug Trial Radar · NCT00696969

Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis

Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL).

Last checked: Nov 19, 2026Latest source record: Feb 11, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 634 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

634

Actual

Start

Jun 2008

Primary completion

Jan 2010

Study completion Jan 2010

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this trial is to identify a safe and effective combination, (coadministration) short course treatment for the treatment of visceral leishmaniasis which could be easily deployed in a control programme and will reduce the risk of parasite resistance occurring. Safety and tolerability should be such that the combination can be easily deployed.

Conditions

  • Visceral Leishmaniasis

Interventions

  • Amphotericin B DeoxycholateDrug

    1 mg/kg e.o.d for 30 days

  • Ambisome + MiltefosineDrug

    Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days

  • Ambisome and ParomomycinDrug

    Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days

  • Miltefosine and ParomomycinDrug

    Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Definitive cure based on parasitological clearance at Day 15 after start of combination therapy (Day 31 for standard therapy), no evidence of parasites at day 45 and no clinical signs or symptoms of VL at 6 months post treatment.Time frame: 6 months post treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kala-azar medical centre

    Muzaffarpur, Bihar, India

  • Rajendra Memorial research Institute

    Patna, Bihar, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.